A Randomonized, Doulble- Blind Trial to Complare the Efficacy and Safety of Anastrozole (Arimidex 1 Mg daily) wtih Tomaxifen Citrate (20 mg daily) as First- Line Therapy for Advanced Breast Cancer in Post Menopausal Women

Study identifier:1033IL/0030

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomonized, Doulble- Blind Trial to Complare the Efficacy and Safety of Anastrozole (Arimidex 1 Mg daily) wtih Tomaxifen Citrate (20 mg daily) as First- Line Therapy for Advanced Breast Cancer in Post Menopausal Women

Medical condition

Breast Cancer

Phase

Phase 3

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Feb 1996
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria